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Introduction
The term PNS refers to signs or symptoms that result from damage to organs or 
tissues that are far from the site of a malignant neoplasm or its metastases. PNSs 
are much less common than direct, metastatic, and treatment related complications 
of cancer, but are important because they could cause severe neurological 
morbidity and mortality and often present to the neurologist in a patient without a 
known malignancy. Paraneoplastic syndromes can affect most organs and tissues 
(1). Paraneoplastic syndromes happen because the tumor secretes substances, 
which mimic normal hormones or which interfere with circulating proteins. 
Paraneoplastic neurologic disorders are caused by similar mechanisms, such as 
carcinoid myopathy and encephalopathy (2); however, most of PNS are immune-
mediated (3). Obviously, damage to the nervous system by cancer-induced 
coagulopathies or opportunistic infections are not considered to be paraneoplastic 
neurologic disorders.
PNSs are rare, and affecting less than 1/10,000 patients with cancer. PNS can 
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Abstract
Objective 
Paraneoplastic neurological syndromes (PNS) were initially defined 
as neurological syndromes with unknown etiology that often associate 
with cancer. This broad definition may lead to misconception that 
any neurological syndrome, which coincides with a cancer might be 
considered as PNS. In the last two decades it has been suggested that PNSs 
are mainly immune-mediated. The detection of onconeural antibodies 
has been very helpful in indicating the existence of a tumor and defining 
a given neurological syndrome as paraneoplastic. However, PNS may 
occur without onconeural antibodies, and the antibodies can occur with 
no neurological syndrome; thus, their presence should not be the only 
condition to define a neurological syndrome as paraneoplastic. Diagnosis 
of paraneoplastic syndromes in children may result in early detection and 
treatment of the pediatric cancer and can reduce the neurological damage 
that is the major source of morbidity in children with successfully treated 
tumors. This study reviews the presenting symptoms, immunology, and 
management options for paraneoplastic syndromes, focusing on those 
most commonly reported in children.
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Criteria for definite PNS
1- A classical neurologic syndrome (according to the 
syndromes defined in Table 1) and cancer that develops 
whitin five years of the diagnosis of the neurological 
disorder. In this setting, the presence of onconeural 
antibodies is not necessary. The time period of five years 
has been derived from previous work that revealed in 
patients with classical syndromes, the tumor is nearly 
always diagnosed within five years following the onset 
of the PNS (8,10).
2. A non-classical neurologic syndrome that resolves 
or significantly improves after chemotherapy without 
concomitant immunotherapy, provided that the 
syndrome is not susceptible to spontaneous remission. 
PNS should not been applied to patients whose 
treatment of the tumor consisted of drugs that are 
immunosuppressive and these drugs are known to be 
able to improve the associated neurological syndrome 
(7).
3. A non-classical syndrome with onconeural antibodies 
(well characterized or not) and cancer that develops 
within five years of the diagnosis of the neurological 
disorder (6).
4. A neurological syndrome (classical or not) with well 
characterized onconeural antibodies (anti-Hu,Yo, CV2, 
Ri, Ma2, or amphiphysin) and no cancer. 
This set of criteria may have a very small number of false 
positive cases that will never develop cancer despite the 
presence of well characterized onconeural antibodies 
(Table 2). A conceivable explanation is that the tumor 
was eliminated by the immune response (1). In contrast, 
anti-Tr antibodies cannot be used for classification of the 
PNS as definite in the absence of cancer, because 11% 
of patients reported that never developed Hodgkin’s 
disease and the antibody disappeared in the follow-up 
(11).
Criteria for possible PNS
1. A classical syndrome, no onconeural antibodies, no 
cancer but at high risk to have an underlying tumour. 
Some classical syndromes are not related to onconeural 
antibodies and may also occur in the absence of cancer. 
The diagnosis of cancer in the follow-up is the only 
way to define the syndrome as definite PNS. All these 
patients should have at least an initial cause for cancer. 
affect various parts of the central and peripheral 
nervous system, the neuromuscular junction, and 
muscle. They can be isolated or occur in association. 
Paraneoplastic neurologic disorders are usually severe, 
often disabling, and sometimes lethal (4). In most of 
patients, the neurological disorder develops prior to 
the cancer becomes clinically obvious and the patient 
is referred to the neurologist who is responsible for 
identifying a neurological disorder as paraneoplastic 
(5). In the last two decades, it has been approved that 
some PNSs are associated with antibodies against 
antigens that are expressed by both the tumor and the 
nervous system (onconeural antibodies). Although 
numerous types of paraneoplastic antibodies have been 
described (1,6-8), less than half of patients with PNS 
bear paraneoplastic antibodies (7). Thus, the absence of 
paraneoplastic antibodies cannot rule out the diagnosis 
of PNS. Many reports suggest that patients who suffer 
from paraneoplastic neurologic disorders have a better 
prognosis than patients with histologically identical 
tumors that are not associated with paraneoplastic 
neurologic disorders (9). In November 2002, an 
international panel of neurologists who were interested 
in the field of PNS started to establish guidelines 
to provide more strict diagnostic criteria for PNS. 
According to their discussion, the panel concluded that 
the diagnostic criteria of a neurological syndrome as 
paraneoplastic must be based on the presence or absence 
of cancer and the definitions of classical versus non-
classical syndromes and well characterized onconeural 
antibody (7).
Diagnostic criteria for PNS
The panel suggested that there should be two levels 
of diagnostic evidence for definition of a neurological 
syndrome as paraneoplastic: “definite” and “possible”. 
Each level can be reached combining a series of criteria. 
The panel recognized that the term “possible” can 
include true PNS, but also the coincidental relationship 
of two independent disorders (the neurological 
syndrome and cancer) should also be considered. The 
panel emphasized that definite and possible PNS have 
in common the requirement to exclude other known 
causes that can clarify the neurological syndrome, even 
if onconeural antibodies are positive (7).
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To reduce false-positive diagnosis of possible PNS, 
the panel decided to limit the time period between the 
neurological syndrome and the diagnosis of cancer 
to two years. Although, some cases of sensorimotor 
neuropathy were considered potential PNS early in the 
description of these syndromes, they are clinically and 
neurophysiologically heterogeneous and are associated 
with various tumor types (12).
Classical syndromes
The term ‘‘classical syndrome’’ applies to those 
neurological syndromes that frequently associate 
with cancer (Table 1). The diagnosis of a classical 
syndrome should prompt to investigate an occult tumor 
regardless of the antibody status. In adults, it has been 
estimated that about 3–5% of patients with small cell 
lung cancer, 15-20% with thymomas, and 3–10% with 
B-cell or plasma-cell neoplasms develop paraneoplastic 
neurologic disorders. The prevalence in cancer of the 
breast or ovary and other neoplasms is lower than 1% 
(13).
If cancer never develops after five years, the syndrome 
should not be included in possible PNS category. 
There are some clues that can assist neurologists to 
predict which patients with these classical syndromes 
are at high risk for an underlying cancer. The panel’s 
recommendation is that the diagnosis of possible PNS 
in the setting of the present criteria should apply only to 
those classical syndromes that also have the identified 
risks for an underlying tumor.
2. A neurological syndrome (classical or not) with 
partially characterized onconeural antibodies and no 
cancer. Partially characterized onconeural antibodies 
are infrequently seen in patients without cancer. Hence, 
the neurological syndromes that fulfill the above defined 
criteria should be considered possible PNS until the 
follow-up confirms or not the presence of an underlying 
tumor.
3. A non-classical neurological syndrome, no 
onconeural antibodies, and cancer present within 
two years of diagnosis: this definition may include 
neurological syndromes, in which we cannot rule out a 
casual association with as common an event as cancer. 
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Table 1. Classical Paraneoplastic Neurological Syndromes





Syndromes of the peripheral nervous system
Subacute sensory neuronopathy
Chronic gastrointestinal pseudo-obstruction




Cerebrospinal fluid (CSF) shows a mild pleocytosis (30-
40 WBC/mm3) and an elevated IgG level. Pleocytosis 
is usually seen only early in the course of the disease 
and disappears in several weeks to months. The elevated 
IgG1 may, however, persist. Analysis of CSF cells in 
patients with paraneoplastic cerebellar degeneration 
has shown that the predominant cell type (over 75%) 
is T cells, with a small component (less than 10%) of B 
cells and natural killer (NK) cells (14). Many patients 
with paraneoplastic syndromes have antibodies in their 
serum (and CSF), which react with both antigens in the 
nervous system and the underlying cancer. Although, 
there is considerable overlap, each of these antibodies is 
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related to clinical syndromes and a restricted subgroup 
of cancers. These antibodies also suggest the location of 
the underlying cancer. For instance, the existence of anti-
Yo antibodies in the serum of a woman with cerebellar 
symptoms can be a persuasive evidence that she has 
paraneoplastic cerebellar degeneration and ovarian 
cancer. Unfortunately, all patients with paraneoplastic 
syndromes do not have well-known antibodies in their 
serum. Whether this is a technical fault in detection or 
whether it means that some paraneoplastic neurologic 
disorders are not immune-mediated is not known (1). 
However, the antibodies and cytotoxic T-cells that are 
specific for the tumor antigen are not sufficient to cause 
the neurologic disease, unless they cross the blood–
brain barrier and react with neurons that express the 
onconeural antigen (14).
Well characterized onconeural antibodies
In the absence of a detected tumor, only well 
characterized onconeural antibodies (anti-Hu, Yo, 
CV2, Ri, Ma2, amphiphysin) should be applied for 
the classification of the associated disorder as definite 
PNS (Table 2). The term well characterized antibodies 
is based upon (1) antibodies for which there are 
recognizable patterns on routine immunohistochemistry 
and for which immunoblotting on recombinant proteins 
must be used for confirming their specificities (2); the 
number of cases reported to be associated with tumors 
(3); the description of well characterized neurological 
syndromes that are associated with the antibodies (4); 
the definite identification of the antibodies in different 
studies; and (5) frequency of these antibodies in patients 
without cancer (7).
Partially characterized onconeural antibodies 
Partially characterized onconeural antibodies include 
anti-Tr, ANNA3, PCA2, Zic4, and mGluR1. Other 
antineuronal antibodies occasionally detected in one 
or a few patients with PNS should not be utilized 
in the diagnosis of PNS until more data are obtained 
(8). Care must be taken to distinguish those that 
preferentially associate with PNS from those that 
may just reflect an antitumour immune response. 
Antibodies in paraneoplastic neurologic disorders react 
with the portion of the nervous system that accounts 
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for the clinical symptoms, for example, anti Purkinje-
cell antibodies occur in patients with paraneoplastic 
cerebellar degeneration (15). In paraneoplastic 
neurologic disorders that affect the brain, relatively 
high titers of the antibody in the CSF (relative to total 
IgG) show that the antibody is synthesized within the 
brain, probably by specific B cells that have crossed 
the blood-brain barrier (16). However, different 
paraneoplastic neurologic disorders may have various 
underlying mechanisms. When the target antigens 
are cell-surface receptors, like in the Lambert-Eaton 
myasthenic syndrome, myasthenia gravis, and a 
rare form of paraneoplastic cerebellar degeneration, 
antibodies can play a predominant role (1,14,16). In 
the current model, apoptosis of tumor cells triggers an 
antitumor immune response. Actually, apoptotic tumor 
cells in paraneoplastic neurologic disorders are strong 
stimulators of activating tumor-specific T cells. Such 
killer T cells can trigger a feedback loop via inducing 
apoptosis and therefore amplification of the antitumor 
immune response (17,18).
Table 2. Well Characterized Onconeuronal Antibodies 
and Related Tumors
Anti-Hu (ANNA1) Small cell lung cancer
Anti-Yo (PCA1) Ovary, breast
Anti-CV2 (CRMP5) Small cell lung canc, thymoma
Anti-Ri (ANNA2) Breast, Small cell lung cancer
Anti-Ma2 (Ta) Testicular, lung
Anti-amphiphysin Breast, Small cell lung cancer
Paraneoplastic neurologic disorders in children
The general criteria for diagnosis of PNSs in adults can 
be applied to children. However, the maximal interval 
period between neurologic symptom presentation 
and demonstration of a tumor, that in adults has been 
suggested to be 5 years, should apparently be tailored 
to a shorter interval taking into account the tumors 
more frequently involved in children (neuroblastoma, 
teratoma, and Hodgkin’s lymphoma) (19). On the 
contrary, they sometimes mask the symptoms of a 
tumor and result in diagnostic delay (20). Although, 
paraneoplastic syndromes can affect any part of the 
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neuraxis in children, the central nervous system is mostly 
affected. The prevalence of paraneoplastic neurologic 
disorders in children has not been known yet. The most 
common paraneoplastic syndromes of CNS in children 
comprise of opsoclonus myoclonus syndrome (OMS), 
limbic encephalitis, and Anti-N-methyl-D-aspartate 
receptor (anti-NMDA-R) encephalitis.
Opsoclonus-myoclonus syndrome
OMS, also called Kinsbourne syndrome or “dancing 
eyes” syndrome, is the most common pediatric 
PNS in the medical literature. Patients may present 
with staggering and falling that often can lead to a 
misdiagnosis of acute cerebellar ataxia. Later, they 
may develop myoclonus, drooling, speech problems, 
hypotonia, and sleep disturbance (19). The duration of 
the time between presentation of neurologic symptoms 
and diagnosis of tumor in children varies between 1 
week to 20 months after symptom onset (21). Most of the 
paraneoplastic syndromes in children are believed to be 
immune-mediated. The major explanation is that when 
proteins which are normally restricted to the nervous 
system become ectopically expressed in a cancer, the 
immune system recognizes the neural antigen (in the 
cancer) as foreign and elicits an attack, which may 
result in antineoplastic effects but also causes severe 
neurologic symptoms (19). In most cases, antibodies 
react with cell surface antigens and play a direct role 
in causing the neurologic disorders. Some of the PNSs 
seem to be mediated by a specific antigen-driven 
clonal expansion of T cells, in which T-cell immune 
responses are directed against the target antigens and 
finally, some cases of OMS may be both B-cell and 
T-cell mediated (13,19). In children, syndrome of 
opsoclonus, cerebellar ataxia, and myoclonus occurs 
mainly as a paraneoplastic syndrome related to occult, 
low-grade neuroblastoma (stage I or II). The syndrome 
occurs almost exclusively in young children (6 months 
to 3 years of age) and is generally considered to occur 
in about 2% to 3% of children with neuroblastoma 
(22,23). Survival in children with neuroblastoma 
presenting with opsoclonus-ataxia is significantly 
higher than in children with neuroblastoma without 
neurologic presentation (9,23).
Antibody search
A paraneoplastic panel should be performed on the 
serum and possibly the CSF. If clinical suspicion is 
high, it is recommended that a tumor search be initiated 
at the time the antibody panel is sent. Antibodies do not 
have specificity and sensitivity in children, especially 
for neuroblastoma, and classic or atypical OMS. If 
paraneoplastic antibodies are present in association 
with these symptoms, the patient should be assumed 
to have an occult neoplasm until proven otherwise 
(21). In children with opsoclonus-ataxia, antineuronal 
antibodies are less consistently found and their related 
antigen is still unclear, although Connolly et al. reported 
antibodies to various components of cerebellar neurons 
in at least some children with opsoclonus-ataxia (24). 
Some researchers have found that serum autoantibodies 
against cell-surface antigens on cerebellar granular 
neurons and neuroblastoma cells, and incubation of 
these autoantibodies with neuroblastoma cell lines 
inhibits cell proliferation and induces apoptosis 
(25,26). However, these data could not be reproduced 
by other researchers using serum of patients with adult 
OMS (27).
Tumor search
In general, a tumor search includes imaging of the neck, 
chest, abdomen, and pelvis, including testes in boys. 
A survey of OMS in UK showed wide variability in 
approaches, with MRI being more commonly done in 
children neuroblastoma. One fourth of neuroblastoma 
positive children initially had both a negative chest x-ray 
and abdominal ultrasound and the tumor was diagnosed 
with MRI (28). A UK report in 1994 on 54 patients 
with OMS showed neuroblastoma in only four patients, 
which increase the possibility that occult tumors were 
missed by the imaging modalities available at the time 
(29). After MRI, whole-body fluorodeoxyglucose–
positron emission tomography (FDG-PET) may be 
needed to detect the tumor. In a study on 20 patients 
with paraneoplastic antibodies, in whom conventional 
imaging gave negative or uncertain results for the 
presence of tumor, abnormal uptake was found in 18 
patients, 14 of whom had a histologically confirmed 
tumor (30). Pediatric neurologists may want to consider 
using FDG-PET more often, although no studies have 
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compared FDG-PET to MRI for this intention. Lately, 
an European task force suggested thoracic CT followed 
by FDG-PET and pelvic ultrasound followed by CT. 
It is not obvious why MRI was not recommended. 
It is also recommended to repeat initial screening 
after 3-6 months and screening every 6 months up 
till 4 years (30). To search for neuroblastoma, tests 
should moreover include catecholamine metabolites 
(e.g., vanillylmandelic acid and homovanillic acid) 
in the urine, and nuclear scintigraphy studies using 
radioiodinated metaiodobenzylguanidine (MIBG) (31).
Limbic encephalitis and anti - NMDA receptor 
encephalitis
Typical features that suggest involvement of the limbic 
system comprise personality changes, irritability, 
seizures, cognitive dysfunction, and memory loss. 
Retrospective studies indicate paraneoplastic 
syndromes may represent approximately 10% of 
pediatric limbic encephalitis cases (32). The most 
frequently associated neoplasms in children are 
Hodgkin lymphoma, ovarian teratoma, or testicular 
tumor. Neuroblastoma has also been reported (33). In 
adults, neurologic symptoms in paraneoplastic limbic 
encephalitis precede the cancer diagnosis in 60% of 
patients with a median of 3.5 months, and this number 
may be higher in children (34). The diagnosis of limbic 
encephalitis is clinical and its confirmation in adults 
requires CSF analysis, MRI demonstrating temporal 
lobe abnormalities, or electroencephalogram showing 
epileptic activity or slowing in the temporal lobes 
(34). There are no studies that examine the sensitivity 
and specificity of diagnostic methods in children with 
limbic encephalitis. Onconeuronal antibodies are 
detected in the serum and CSF of 60% of adult patients 
with paraneoplastic limbic encephalitis (36). Various 
antibodies and tumors have been reported, such as anti-
Hu/ANNA-1 (small cell lung cancer), anti-Ri/ANNA-
2 (lung or breast cancer), anti-Ma2 (lung, breast, or 
testicular cancer), anti-CV2/CRMP5 (small cell lung 
cancer), and anti-amphiphysin (breast, small cell lung 
cancer) (34,35). Most antibodies and associated tumors 
are rare or not occurring in children.
NMDA receptor antibodies
Anti - N - methyl - D - aspartate receptor (NMDAR) 
encephalitis is a recently described paraneoplastic 
syndrome that is increasingly recognized in children 
and adolescents. Since the first case reports in 2007 
(36, 37) and a series in 2008 (38), hundreds of cases 
of paraneoplastic and non paraneoplastic anti-
NMDAR encephalitis have been stated in the literature. 
Children with NMDAR encephalitis have prominent 
neuropsychiatric abnormalities, including behavioral or 
personality change, sleep dysfunction, dyskinesias or 
dystonias, autonomic instability, and speech reduction 
(39). Like other encephalitis, supporting evidence 
consists of CSF lymphocytic pleocytosis or oligoclonal 
bands demonstrating an inflammatory or immune-
mediated process, EEG with slow, disorganized activity 
and infrequent seizures, and brain MRI that shows 
transient flair or contrast-enhancing abnormalities in 
cortical and subcortical regions, limbic areas, basal 
ganglia, brainstem, cerebellum, and sometimes white 
matter (39).
Other paraneoplastic neurologic syndromes in pediatrics
Other cases of paraneoplastic syndromes have been 
reported in children. As in adults, there may be 
overlap among the various paraneoplastic syndromes. 
For example, it has been observed that patients 
with encephalitis have gastrointestinal dysmotility 
and sensory neuropathies (40). Hodgkin’s disease 
has been associated with paraneoplastic neurologic 
syndromes in children, including a case report of 
cerebellar degeneration and Horner syndrome (41). 
Children may have been found to have paraneoplastic 
disorders of neuromuscular transmission. Lambert-
Eaton myasthenic syndrome characterized by muscle 
weakness, hyporeflexia, and autonomic dysfunction 
is associated with cancer in approximately 50% of 
cases, typically small cell lung cancer in adults and 
neuroblastoma in children (42).
Treatment Overview
In any paraneoplastic syndrome in children, initial 
treatment must focus on the removal and treatment of 
the tumor. Almost all paraneoplastic syndromes have 
some improvement in neurologic symptoms following 
tumor removal (43). Most of the CNS paraneoplastic 
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with memory, cognitive, and motor deficits or died of 
the disorder (39). In 31 patients with paraneoplastic 
or non-paraneoplastic anti-NMDAR encephalitis, 30 
(97%) had immunotherapy, including a combination of 
corticosteroids, IVIG, or plasma exchange (39).
Finally, it is important to emphasize that in about 20% 
of cases, no cancer is ever found, even at postmortem 
examination, probably indicating the successful control 
of tumor growth and metastasis by the host immune 
system in patients with araneoplastic neurologic 
disorder. Meanwhile, there are very rare associations 
of other conditions with malignancies in children that 
should not interpreted as paraneoplastic syndromes. 
Alavi et al. have reported a very rare occurrence of 
kawasaki disease concurrent with neuroblastoma (48), 
whereas it should not be interpreted as paraneoplastic 
syndrome.
In conclusion, PNSs are rare disorders so that even 
neurologists encounter only a few patients in their 
routine practice. The information collected from 
referring neurologists may be short of detailed clinical 
or paraclinical information, which may be important 
for a better definition of PNS. The diagnostic criteria 
presented in this review article may assist neurologists to 
report their patients with PNS more uniformly. The most 
important limitation in this field is the facilities to detect 
onconeural antibodies, since they have not been widely 
standardized, and with the discovery of new onconeural 
antibodies, care must be taken to differentiate those that 
associate with PNS from those that may just reflect an 
antitumour immune response. The future will provide 
evidence if these recommendations have been useful to 
improve the diagnostic accuracy and researches in the 
field of PNS.
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